Tissue MiR-193b As a Novel Biomarker for Patients with Ovarian Cancer

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2015 Dec 18

PMID 26675282

Citations 23

Authors

Haiyan Li

Yuping Xu

Weifeng Qiu

Danni Zhao

Yuanzhen Zhang

Affiliations

Soon will be listed here.

Abstract

BACKGROUND MiRNAs play important roles in regulating many fundamental biological processes. Deregulation of miRNAs is involved in the initiation and progression of cancer. MiR-193b is regarded as tumor suppressor in many types of cancers. However, the role of miR-193b in ovarian cancer is poorly understood. MATERIAL AND METHODS The expression level of miR-193b in ovarian cancer cell lines and ovarian cancer samples was evaluated using quantitative real-time reverse transcription-PCR (qRT-PCR). The ovarian cancer patients were categorized into a high miR-193b expression group and a low miR-193b expression group according to the median miR-193b expression level. The correlation between tissue miR-193b expression and the patients' clinicopathological factors, as well as survival, was also analyzed. RESULTS The results showed that the miR-193b expression was significantly down-regulated in ovarian cancer cell lines and tumor tissues compared with normal controls. In addition, tissue miR-193b expression was positively correlated with FIGO stage (P=0.001), histological grade (P=0.032), ascites (P=0.019), lymph node metastasis (P=0.003), and tumor size (P=0.041). Among 116 patients with ovarian cancer examined, the 5-year overall survival (OS) rates were 62.5% and 22.01% in patients with high and low miR-193b expression, respectively (P=0.003). Multivariate analysis showed that tissue miR-193b is an independent prognostic factor in patients with ovarian cancer (HR=4.219; P=0.015). CONCLUSIONS Reduction of miR-193b was found in ovarian cancer and its lower expression was associated with poorer prognosis. Tissue miR-193b showed potential as novel biomarker for ovarian cancer.

Citing Articles

Utilization of miRNAs as Biomarkers for the Diagnosis, Prognosis, and Metastasis in Gynecological Malignancies.

Lazaridis A, Katifelis H, Kalampokas E, Lambropoulou D, Aravantinos G, Gazouli M Int J Mol Sci. 2024; 25(21).

PMID: 39519256 PMC: 11546551. DOI: 10.3390/ijms252111703.

MiR-193b as an effective biomarker in human cancer prognosis for Asian patients: a meta-analysis.

Yu H, Peng Y, Wu Z, Wang M, Jiang X Transl Cancer Res. 2022; 11(7):2249-2261.

PMID: 35966293 PMC: 9372259. DOI: 10.21037/tcr-21-2557.

MicroRNAs as Biomarkers for Early Diagnosis, Prognosis, and Therapeutic Targeting of Ovarian Cancer.

Mirahmadi Y, Nabavi R, Taheri F, Samadian M, Ghale-Noie Z, Farjami M J Oncol. 2021; 2021:3408937.

PMID: 34721577 PMC: 8553480. DOI: 10.1155/2021/3408937.

High expression level of miR-1260 family in the peripheral blood of patients with ovarian carcinoma.

Ghafour A, Odemis D, Tuncer S, Kurt B, Saral M, Erciyas S J Ovarian Res. 2021; 14(1):131.

PMID: 34629107 PMC: 8504092. DOI: 10.1186/s13048-021-00878-x.

Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer.

Liu S, Wu M, Wang F J Cancer. 2021; 12(13):3976-3996.

PMID: 34093804 PMC: 8176232. DOI: 10.7150/jca.47695.

References

Chen X, Chen Y, Lan J, Shen Z . MicroRNA-370 suppresses proliferation and promotes endometrioid ovarian cancer chemosensitivity to cDDP by negatively regulating ENG. Cancer Lett. 2014; 353(2):201-10. DOI: 10.1016/j.canlet.2014.07.026. View

Suh D, Kim K, Kim J . Major clinical research advances in gynecologic cancer in 2011. J Gynecol Oncol. 2012; 23(1):53-64. PMC: 3280068. DOI: 10.3802/jgo.2012.23.1.53. View

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

Esteller M . Non-coding RNAs in human disease. Nat Rev Genet. 2011; 12(12):861-74. DOI: 10.1038/nrg3074. View

Lenarduzzi M, Hui A, Alajez N, Shi W, Williams J, Yue S . MicroRNA-193b enhances tumor progression via down regulation of neurofibromin 1. PLoS One. 2013; 8(1):e53765. PMC: 3546079. DOI: 10.1371/journal.pone.0053765. View

Nakano H, Yamada Y, Miyazawa T, Yoshida T . Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells. Int J Oncol. 2013; 42(6):1875-82. PMC: 3699598. DOI: 10.3892/ijo.2013.1896. View

Mets E, van der Meulen J, Van Peer G, Boice M, Mestdagh P, Van de Walle I . MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemia. Leukemia. 2014; 29(4):798-806. PMC: 4890642. DOI: 10.1038/leu.2014.276. View

Choi Y, Pan Y, Park E, Konstantinopoulos P, De S, DAndrea A . MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability. Elife. 2014; 3:e02445. PMC: 4031983. DOI: 10.7554/eLife.02445. View

Liu X, Chong Y, Liu H, Han Y, Niu M . Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer. J Ovarian Res. 2015; 8:35. PMC: 4465006. DOI: 10.1186/s13048-015-0166-y. View

10.

Ziliak D, Gamazon E, Lacroix B, Im H, Wen Y, Huang R . Genetic variation that predicts platinum sensitivity reveals the role of miR-193b* in chemotherapeutic susceptibility. Mol Cancer Ther. 2012; 11(9):2054-61. PMC: 3438340. DOI: 10.1158/1535-7163.MCT-12-0221. View

11.

Xu C, Liu S, Fu H, Li S, Tie Y, Zhu J . MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. Eur J Cancer. 2010; 46(15):2828-36. DOI: 10.1016/j.ejca.2010.06.127. View

12.

Rauhala H, Jalava S, Isotalo J, Bracken H, Lehmusvaara S, Tammela T . miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer. 2010; 127(6):1363-72. DOI: 10.1002/ijc.25162. View

13.

Winter J, Jung S, Keller S, Gregory R, Diederichs S . Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009; 11(3):228-34. DOI: 10.1038/ncb0309-228. View

14.

Liu J, Matulonis U . New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances. Clin Cancer Res. 2014; 20(20):5150-6. DOI: 10.1158/1078-0432.CCR-14-1312. View

15.

Zhong Q, Wang T, Lu P, Zhang R, Zou J, Yuan S . miR-193b promotes cell proliferation by targeting Smad3 in human glioma. J Neurosci Res. 2014; 92(5):619-26. DOI: 10.1002/jnr.23339. View

16.

Mitra A, Chiang C, Tiwari P, Tomar S, Watters K, Peter M . Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis. Oncogene. 2015; 34(48):5923-32. PMC: 4580483. DOI: 10.1038/onc.2015.43. View

17.

Li X, Yan P, Shao Z . Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene. 2009; 28(44):3937-48. DOI: 10.1038/onc.2009.245. View

18.

Zhang B, Pan X, Cobb G, Anderson T . microRNAs as oncogenes and tumor suppressors. Dev Biol. 2006; 302(1):1-12. DOI: 10.1016/j.ydbio.2006.08.028. View

19.

Caramuta S, Egyhazi S, Rodolfo M, Witten D, Hansson J, Larsson C . MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol. 2010; 130(8):2062-70. DOI: 10.1038/jid.2010.63. View

20.

Xia Y, Gao Y . MicroRNA-181b promotes ovarian cancer cell growth and invasion by targeting LATS2. Biochem Biophys Res Commun. 2014; 447(3):446-51. DOI: 10.1016/j.bbrc.2014.04.027. View